PL2368999T3 - Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania - Google Patents

Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania

Info

Publication number
PL2368999T3
PL2368999T3 PL11004496T PL11004496T PL2368999T3 PL 2368999 T3 PL2368999 T3 PL 2368999T3 PL 11004496 T PL11004496 T PL 11004496T PL 11004496 T PL11004496 T PL 11004496T PL 2368999 T3 PL2368999 T3 PL 2368999T3
Authority
PL
Poland
Prior art keywords
amino acid
alkaline phosphatase
kits
methods
bone targeted
Prior art date
Application number
PL11004496T
Other languages
English (en)
Polish (pl)
Inventor
Philippe Crine
Guy Boileau
Thomas P Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of PL2368999T3 publication Critical patent/PL2368999T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL11004496T 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania PL2368999T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
EP08757088A EP2158319B1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof
EP11004496.3A EP2368999B1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2368999T3 true PL2368999T3 (pl) 2014-08-29

Family

ID=40001639

Family Applications (3)

Application Number Title Priority Date Filing Date
PL11004496T PL2368999T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy oraz metody wykorzystywania
PL13002327T PL2662448T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy i sposoby jej zastosowania
PL08757088T PL2158319T4 (pl) 2007-05-11 2008-05-12 Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL13002327T PL2662448T3 (pl) 2007-05-11 2008-05-12 Kierowana do kości fosfataza alkaliczna, zestawy i sposoby jej zastosowania
PL08757088T PL2158319T4 (pl) 2007-05-11 2008-05-12 Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie

Country Status (25)

Country Link
US (1) US20100297119A1 (show.php)
EP (3) EP2662448B1 (show.php)
JP (1) JP5732603B2 (show.php)
AT (1) ATE536413T1 (show.php)
AU (1) AU2008250945B2 (show.php)
BR (2) BR122019000505B1 (show.php)
CA (1) CA2687001C (show.php)
CY (1) CY2016005I1 (show.php)
DE (1) DE202008018131U1 (show.php)
DK (3) DK2662448T3 (show.php)
ES (3) ES2471915T3 (show.php)
FR (1) FR16C0007I2 (show.php)
HR (1) HRP20140416T1 (show.php)
HU (2) HUE031655T2 (show.php)
IL (1) IL202057A0 (show.php)
LT (1) LTC2368999I2 (show.php)
LU (1) LU92976I2 (show.php)
ME (1) ME01828B (show.php)
NL (1) NL300798I1 (show.php)
NO (1) NO2016002I1 (show.php)
PL (3) PL2368999T3 (show.php)
PT (3) PT2662448T (show.php)
RS (1) RS53302B (show.php)
SI (2) SI2662448T1 (show.php)
WO (1) WO2008138131A1 (show.php)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505551T1 (de) 2004-04-21 2011-04-15 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
MX2009013004A (es) 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
JP5986986B2 (ja) * 2010-04-30 2016-09-06 アレクシオン ファーマシューティカルズ, インコーポレイテッド 基質石灰化障害を治療する方法、組成物、およびキット
US20130156765A1 (en) 2010-07-28 2013-06-20 David S. Block FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
HK1210792A1 (en) 2012-08-20 2016-05-06 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
CN111778228A (zh) 2014-01-24 2020-10-16 安-法玛公司 嵌合型碱性磷酸酶样蛋白
WO2016007873A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) * 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
JP6993961B2 (ja) * 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) * 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
US20200306350A1 (en) 2016-06-27 2020-10-01 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN110114065A (zh) * 2016-11-30 2019-08-09 珀杜研究基金会 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
US20220348977A1 (en) * 2017-03-09 2022-11-03 Alexion Pharmaceuticals, Inc. Glycoprotein manufacturing process
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ, インコーポレイテッド 成人及び青年における低ホスファターゼ症(hpp)を治療する方法
CA3096821A1 (en) 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499283A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备改善低碱性磷酸酯酶症干细胞成骨分化能力异常产品中的应用
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
CN116848146A (zh) * 2020-09-03 2023-10-03 I·S·Y·陈 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
EP4291224A4 (en) * 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU1920201A (en) 1999-11-16 2001-05-30 Genzyme Corporation Improved regulatory elements for delivery to the liver
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
ATE505551T1 (de) * 2004-04-21 2011-04-15 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法

Also Published As

Publication number Publication date
BRPI0811198B1 (pt) 2021-03-09
RS53302B (sr) 2014-08-29
HRP20140416T1 (hr) 2014-06-20
SI2368999T1 (sl) 2014-07-31
WO2008138131A4 (en) 2008-12-31
PL2158319T3 (pl) 2012-05-31
HK1191372A1 (en) 2014-07-25
HK1141047A1 (en) 2010-10-29
FR16C0007I1 (show.php) 2016-04-15
FR16C0007I2 (fr) 2017-01-27
BR122019000505B1 (pt) 2022-01-18
EP2662448B1 (en) 2016-12-21
CA2687001C (en) 2019-02-12
LTC2368999I2 (lt) 2017-09-25
PT2368999E (pt) 2014-05-26
AU2008250945A1 (en) 2008-11-20
WO2008138131A1 (en) 2008-11-20
PL2662448T3 (pl) 2017-07-31
NL300798I2 (show.php) 2016-03-16
EP2158319A4 (en) 2010-07-21
EP2158319B1 (en) 2011-12-07
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
NO2016002I2 (no) 2016-02-02
AU2008250945A2 (en) 2009-12-24
ATE536413T1 (de) 2011-12-15
CY2016005I2 (el) 2016-08-31
CY2016005I1 (el) 2016-08-31
DE202008018131U1 (de) 2011-12-30
LTPA2016004I1 (lt) 2016-02-25
HUS1600005I1 (hu) 2016-02-29
CA2687001A1 (en) 2008-11-20
JP5732603B2 (ja) 2015-06-10
EP2158319A1 (en) 2010-03-03
PT2662448T (pt) 2017-03-29
SI2662448T1 (sl) 2017-05-31
EP2368999A1 (en) 2011-09-28
LU92976I2 (en) 2016-04-11
ES2619332T3 (es) 2017-06-26
BRPI0811198A8 (pt) 2018-08-14
EP2368999B1 (en) 2014-03-12
NO2016002I1 (no) 2016-02-02
NL300798I1 (show.php) 2016-03-16
HK1162589A1 (en) 2012-08-31
ES2380546T3 (es) 2012-05-16
PL2158319T4 (pl) 2016-04-29
ME01828B (me) 2014-12-20
US20100297119A1 (en) 2010-11-25
BR122019000505A2 (pt) 2021-12-14
BRPI0811198A2 (pt) 2014-10-21
DK2662448T3 (en) 2017-03-20
DK2158319T3 (da) 2012-03-19
JP2010526543A (ja) 2010-08-05
ES2471915T3 (es) 2014-06-27
PT2158319E (pt) 2012-03-06
DK2368999T3 (da) 2014-05-26
WO2008138131A9 (en) 2009-08-06
AU2008250945B2 (en) 2013-12-12
IL202057A0 (en) 2011-08-01
BRPI0811198B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NL300798I2 (show.php)
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
BRPI0414598A (pt) indóis substituìdos
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
MX347545B (es) Polipeptidos con actividad xilanasa.
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
HUP0101317A2 (hu) Módosított VIII-as faktor
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
BR0110999A (pt) Misturas de adesivos aquosos
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
DK2084198T3 (da) Beklædningssammensætning
EP2004352A4 (en) AMINO ACID SUPPLEMENT FOR PEPTIDE CONSTRUCTIONS
MY150639A (en) T cell adhesion molecule and antibody thereto
TW200731985A (en) A composition for wound healing and use thereof